ACCESS Newswire Q1 2026 rev $5.3M (-3% YoY); adj EBITDA $0.6M consistent; ARR/sub $12,803

ACCESS Newswire Inc.

2026-Q1 EPS reported -$0.16 vs consensus $0.14 ▼ miss (-216.2%)

Revenue $5.3M, down 3% YoY and 8% QoQ; gross margin 74% vs 78% in Q1 2025.
GAAP net loss from continuing ops $0.6M ($0.16 diluted EPS) vs $0.8M loss ($0.20) a year ago.
Adjusted EBITDA $0.6M (11% revenue), equal to Q1 2025; operating cash flow $871k vs $258k in Q4 2025.
Average ARR per subscription customer $12,803 (up 15% YoY from $11,139); subscriber count 1,119 with 180 new adds.
Customer retention 92%; new products: ACCESS Verified AI and Social Monitoring platform launched.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ACCESS Newswire Inc. reported the three months ended March 31, 2026 results: revenue $5.3M, net income $0.6M, or $0.16 per diluted share, EPS $0.16 per diluted share.

Period: the three months ended March 31, 2026
Revenue: $5.3M
Net income: $0.6M, or $0.16 per diluted share
EPS: $0.16 per diluted share
Result: reported results

Exact text from the filing

end of Q1 2026 was $12,803, up from $11,139 at the end of Q1 2025 · Q1 2026 Adjusted EBITDA remained consistent at $564,000 compared to Q1 2025 · Q1 2026 revenue decreased to $5.3M compared to $5.8M in Q4 2025 and $5.5M in Q1 2025 · Gross margin decreased to 74% compared to 78% in Q1 2025 · Cash flow from operations increased to $871,000 compared to

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

ACCESS Newswire Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.